Derivation of cochlear cells from pathological or isogenic human iPSCs for modeling hereditary hearing loss by Czajkowski, Amandine et al.
Amandine CZAJKOWSKI1, Grobarczyk Benjamin1, Laurence Borgs1, Kevin Hanon1, Philippe Lefebvre2, 
Laurent Nguyen1 and Brigitte Malgrange1 
1. GIGA-Neurosciences, Developmental Neurobiology Unit, University of Liège, Belgium 
2. Department of Otorhinolaryngology, University of Liège, Belgium 
Derivation of cochlear cells from pathological or isogenic human 
iPSCs for modeling hereditary hearing loss. 
Alström Syndrome (AS) is a human autosomal recessive genetic disorder characterized by numerous clinical symptoms 
including deafness. AS is caused by mutations in the ALMS1 gene encoding for ALMS1 protein which is expressed at the basal 
body and implicated in ciliogenesis, cell cycle and proliferation (Jagger et al., 2011; Zulato et al., 2011 & Shenje et al., 2014). 
We are interesting in understanding the unknown mechanisms involving this protein in the genetic deafness of AS patients.  To 
develop a model as closer as possible to the human pathology, we are using human induced pluripotent stem cells (hiPSCs) 
generated from fibroblasts of healthy and AS patients. Using a stepwise protocol, we demonstrated that healthy hiPSCs 
(waiting for isogenic hiPSCs) can generate a population of cells with  gene and protein expression patterns consistent with the 
ones of otic progenitor cells (OSCs). In these OSCs, we observed some proliferation defects and an increase in apoptosis tin the 
AS cells compared to the WT. When human OSCs are co-cultured with mouse feeder cells, they are able to differentiate into 
hair cells (HCs). We successfully differentiated AS hiPSCs into HCs. We are currently confirming gene expression pattern and 
testing HCs functionality.  To exclude patient linked epigenetics and differentiation defects, we are correcting the genomic 
mutation in the AS hiPSCs to generate isogenic hiPSCs using the CRIPSR/Cas9 system. Thanks to the isogenic hiPSCs we will be 


















        Fibroblasts from healthy (WT) and deaf AS 
patients (AS)  were reprogrammed into human 
induced pluripotent stem cells (WT and  AS hiPSCs). 
Fibroblasts were infected by Sendaï virus particles 
containing the Oct4, Sox2, Klf4 and C-myc mRNAs. 
HiPSCs were then characterized before being 
differentiated into cochlear cell types. Reprogrammed 
hiPSCs expressed stem cell markers such as NANOG, 
OCT4, SOX2 and TRA-1-81 by immunofluorescence (1-
A, 1-B) and qRT-PCR (1-C). (1-D) 8 weeks after 
injection in a nude mice, hiPSCs formed teratoma 
containing cells from the 3 germ layers. 
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   Induction of otic progenitor cells (OSCs) 
      The stepwise guidance protocol is based on the inner ear embryonic development and adapted from  Oshima 
et al, 2010 and Chen et al, 2012.  Firstly we induced differentiation of hiPSCs into anterior ectoderm by blocking  
WNT and TGFb pathway and adding IGF1 to the culture medium. Ectodermal cells were then pushed toward an 
otic fate  by high doses of bFGF until day 20. Around 20% of cells observed by immunofluorescence at day 9 were 
positive for PAX2 and the otic markers PAX8 and SIX1 meaning that these cells were OSCs. This number increased 
until day 20 to reach 30% (2-B). We further characterized the obtained OSCs by immunofluorescence (2-A) and 
qPCR (2-C). We measured the expression of PAX6, a transcription factor specifically expressed in optic progenitors 
and neurectoderm cells but not in OSCs as control. In presence of SU4802, a bFGF signaling inhibitor, OSCs were 







At day 20, we changed the medium to have 
proliferative conditions. This culture medium maintains 
OSCs in long term culture. These OSC cultures still 
expressed PAX2, PAX8, SOX9 and Ki67 (2-E). These 
results obtained by immunofluorescence were 
confirmed by qRT-PCR (2-D) errors bars represent   
         Hair cells (HCs) differentiation 
         We cultured WT OSCs on dissociated mouse embryonic cochlear cells (from E14 embryos) which act as 
feeder cells to provide a kind environment for the terminal differentiation of the human OSCs into HCs. After 10 
days of co-culture, we observed by IF some clusters of double positive ATOH1/MYOSIN6 cells (2-F). Using a 
specific antibody against human nuclei we confirmed that  these cells were human OSCs differentiated and not 
feeder cells. HCs were surrounded by mouse cells co-expressing SOX9 and SOX2, two markers of supporting cells 
in the organ of Corti (2-G). Recently, we obtained interesting results regarding the functionality of differentiated 
HCs using FM1-43 (2-H). This dye has the property to enter specifically into HCs by the mechanical channels so to 
label only functional HC. 
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From hiPSCs to OSCs 
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      Surrounding cells              Functional HC 
SEM). Plutipotency genes (such as Nanog, Oct4 and Sox 2) which were highly expressed in WT hiPSCs were 
down-regulated in OSCs. In parallel the mRNA levels of otic markers such as PAX2, PAX8 and SIX1 significantly 
increased. We also observed a decreased expression of neurectoderm PAX6 and SOX1 genes when OSCs were 
placed in proliferative condition. 
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       AS hiPSCs differentiated into AS otic progenitors Higher magnification of AS hiPSCs differentiated into AS OSCs 
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Terminal differentiation into AS HC 
AS OSCs P6 on mEOC – Day 10  
         Differenciation of AS hiPSCs into HCs 
         AS hiPSCs are able to differentiate into pathological 
otic progenitors similarly to WT hiPSCs, as shown by IF 
(3-A, 3-B) and qRT-PCR (3-C). It seemed that terminal 
differentiation into HCs was not affected by the ALMS1 









          Modeling the Alstrom syndrome        
        Results obtained from the differentiation of AS hiPSCs into HCs 
suggest that the differentiation potential of these cells into cochlear 
cells is unaffected in AS patients. However, we observed some 
proliferation defects and increase in apoptosis between healthy and AS 




To be sure that observed phenotypes 
are only due to the ALMS1 disease-
causing mutation, we needed isogenic 
cells. The strategy used to obtain them 
is described in panel 5-A. We used the 
CRISPR/Cas9 genome editing to correct 
the AS hiPSCs STOP mutation. The Cas9 
binding is guided by base-pair 
complementarities between the 
engineered single-guide RNA (gRNA) 
and a genomic DNA target sequence. 
We designed gRNAs complementary to 
the ALMS1 genomic locus (5-B). Using 
the engineered gRNA, the Cas9 will 
induce specific double-stranded break 
(DSB), which can be repaired through 
the Homology Directed Repair (HDR) 
pathway. The HDR mechanism is 
induced by providing a single stranded 
oligo dinucleotide (ssODN) repair 
template to the AS hiPSCs. The ssODN 
contains a FokI site we will use to check 
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We developed a human model to study the impact of ALMS1 mutation. We also performed genome 
editing to obtain isogenic hiPSCs used as a reliable control. We obtained preliminary results indicating that 
ALMS1 mutation does not affect differentiation of hiPSCs into HCs but induces proliferative defects and an 
increase in apoptosis. Identification of molecular mechanisms implicated in these phenotypes is crucial to 
understand the hearing loss in Alström syndrome. 
 Thanks to the University Medical Center Göttingen which has kindly funded my 
bursary and offers me the opportunity to attend the Molecular Biology of Hearing and 
Deafness congress.  
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